Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)

STO:NEWBRY Revenue

Newbury Pharmaceuticals AB had revenue of 8.93M SEK in the quarter ending May 31, 2026, with 33.61% growth. This brings the company's revenue in the last twelve months to 35.02M, down -25.14% year-over-year. In the fiscal year ending August 31, 2025, Newbury Pharmaceuticals AB had annual revenue of 31.57M, down -14.27%.

• Revenue (ttm): 35.02M
• Revenue Growth: -25.14%
• P/S Ratio: 2.26
• Revenue / Employee: 5.00M
• Employees: 7
• Market Cap: 79.03M

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Aug 31, 2025	31.57M	-5.26M	-14.27%
Aug 31, 2024	36.83M	26.56M	258.75%
Aug 31, 2023	10.27M	4.75M	86.11%
Aug 31, 2022	5.52M	2.43M	78.73%
Aug 31, 2021	3.09M	-	-

Data Source: S&P Global Market Intelligence Last updated: May 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 24, 2026

Data Sources Report a data error